schizandrin b has been researched along with Fatty Liver, Nonalcoholic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M; Ma, R; Wang, X; Wu, L; Zhan, Y; Zhang, Y | 1 |
| Cheng, BC; Luo, G; Pan, SY; Qiu, XY; Song, XL; Wang, QG; Wang, YW; Yan, LS; Zhang, C; Zhang, SF; Zhang, Y; Zhou, XH | 1 |
| Chan, CL; Chao, X; Dai, W; Fong, WF; Fu, X; Kwan, HY; Lee, KC; Li, T; Lu, A; Niu, X; Pan, SY; Su, T; Tong, T; Tse, AK; Yi, H; Yu, H; Yu, ZL | 1 |
| Ko, KM; Leong, PK | 1 |
1 review(s) available for schizandrin b and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease.
Topics: Animals; Cyclooctanes; Humans; Lignans; Models, Biological; Non-alcoholic Fatty Liver Disease; Polycyclic Compounds; Protective Agents | 2016 |
3 other study(ies) available for schizandrin b and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Body Weight; Cyclooctanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin Resistance; Lignans; Lipid Metabolism; Lipids; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Polycyclic Compounds; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2022 |
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cyclooctanes; Diet, High-Fat; Fatty Acids, Nonesterified; Hepatocytes; Ketone Bodies; Lignans; Lipid Metabolism; Liver; Mice; Non-alcoholic Fatty Liver Disease; Polycyclic Compounds; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.
Topics: Animals; Cyclooctanes; Diet, High-Fat; Disease Models, Animal; Fasting; Fatty Acid Synthases; Fatty Acids; Lignans; Lipid Metabolism; Lipids; Lipolysis; Liver; Liver Cirrhosis; Male; Metabolic Networks and Pathways; Metabolomics; Mice; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Polycyclic Compounds; Sterol Regulatory Element Binding Protein 1; Tumor Necrosis Factor-alpha | 2015 |